About NANO MRNA

NANO MRNA is pursuing business growth under the strategic objective of establishing a cycle of mRNA medicine intellectual property (IP) creation and licensing as a platform linking mRNA drug discovery seeds and medical and development needs.

Last year, in the mRNA drug pipeline, a therapeutic vaccine project for allergies and autoimmune diseases in collaboration with Kao Corporation progressed to the candidate selection stage. Joint research with Senju Pharmaceutical in the field of ophthalmology is also progressing well. These results will lead to the creation of Intellectual Property in the near future. In addition, we will soon be able to announce the start of Phase I study of RUNX1 mRNA project in patients with knee osteoarthritis, developed in collaboration with the Institute of Science Tokyo.

In the non-mRNA drug pipeline, the Phase I trial of TUG1 ASO in glioblastoma multiform patients, developed in collaboration with Nagoya University, started February last year and has progressed ahead of schedule to dose level 3 of four. No serious adverse events have been reported to date and anti-tumor activity is currently being evaluated.

Last fiscal year, we launched a new contract-based business in mRNA drug discovery for pharmaceutical companies, etc., and we are already carrying out contracts. The collaboration with Crafton Biotechnology, which has been included in the pipeline, is also positioned as a contract-based business, with project funding provided by SCARDA as one of the mechanisms to supplement research and development costs.

This year, the top priority is to start the first-in-human study of RUNX1 mRNA and in parallel we will accelerate the clinical trial of TUG1ASO to explore the possibility of establishing a clinical POC. The goal of both assets is to out-license to pharmaceutical companies, so we will take the appropriate steps for each clinical stage.

We truly appreciate your continued support for our activities.

Sincerely yours,